NasdaqGS - Nasdaq Real Time Price USD

4D Molecular Therapeutics, Inc. (FDMT)

3.7500

+0.1300

+(3.59%)

At close: June 2 at 4:00:02 PM EDT

3.7458

-0.00

(-0.11%)

After hours: June 2 at 6:09:30 PM EDT

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in June. Members of the management team will also be available for one-on-one meetings. Jeffe

GlobeNewswire 5 days ago

FDMT
+3.59%
Spotlight On 3 Penny Stocks With Market Caps Under $500M

In the last week, the market has stayed flat, but it is up 11% over the past year, with earnings expected to grow by 14% per annum over the next few years. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer significant opportunities when built on solid financials. We've selected three examples of penny stocks that combine balance sheet strength with potential for outsized gains, giving investors a chance to discover...

Simply Wall St. 12 days ago

FDMT
+3.59%

VTYX

MYGN
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 13, 2025, the compensation committee of the Company’s board of directors granted eight new non-executive employees 31,800 Restricted Stock Units (RSUs). The RSUs wer

GlobeNewswire 17 days ago

FDMT
+3.59%
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -2.38% and 98.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 25 days ago

FDMT
+3.59%
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027RMAT designation received from FDA for 4D-150 in DME, adding to previous regulatory designations of RMAT and PRIME (EMA) for 4D-150 in wet AMD$458 million in cash, cash equivalents, and marketable securities as of Ma

GlobeNewswire 25 days ago

FDMT
+3.59%
FDA awards RMAT status to 4DMT diabetic macular oedema therapy

The therapy leverages the company’s intravitreal vector, R100, invented using the Therapeutic Vector Evolution platform.

Pharmaceutical Technology last month

FDMT
+3.59%
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema

GlobeNewswire last month

FDMT
+3.59%
Discover Fractyl Health And 2 More Promising Penny Stocks

Over the last 7 days, the United States market has dropped 4.4%, yet earnings are forecast to grow by 13% annually. For those looking to invest in smaller or newer companies, penny stocks can still offer surprising value despite their somewhat outdated name. With solid financial foundations, these stocks have the potential to outperform while offering greater stability, making them intriguing options for investors seeking under-the-radar opportunities with long-term potential.

Simply Wall St. last month

FDMT
+3.59%

TSHA

GUTS
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks 2 months ago

GLPG

GLPGF

PTCT
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 Phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degenera

GlobeNewswire 2 months ago

FDMT
+3.59%
4D Molecular price target lowered to $35 from $39 at RBC Capital

RBC Capital lowered the firm’s price target on 4D Molecular (FDMT) to $35 from $39 but keeps an Outperform rating on the shares after its Q4 results. The company’s first of two wet AMD – wAMD – pivotal studies is on track to initiate this month, with 4D also anticipating the second study to launch in Q3, the analyst tells investors in a research note. 4D Molecular has an ideal benefit/risk profile for wAMD / DME, or diabetic macular edema, and the firm also likes that strategic focus has been sh

TipRanks 2 months ago

FDMT
+3.59%
4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations

4D Molecular Therapeutics ( NASDAQ:FDMT ) Full Year 2024 Results Key Financial Results Net loss: US$160.9m (loss...

Simply Wall St. 2 months ago

FDMT
+3.59%
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and continued favorable tolerability Announced positive interim 32-week data for 4D-150 in DME from Part 1 of SPECTRA clinical trial and alignment with FDA for a single Phase 3 trial being acceptable for the basis of BLA submission for 4D-150 in DME when combined with data generated from 4FRONT P

GlobeNewswire 3 months ago

FDMT
+3.59%
Spotlight On February 2025's Promising Penny Stocks

The U.S. stock market is experiencing mixed signals as investors process recent earnings reports and policy announcements, with the Dow Jones seeing gains while the S&P 500 and Nasdaq face slight declines. Amid these fluctuations, penny stocks present a unique opportunity for investors seeking growth at lower price points. Although often associated with smaller or newer companies, these stocks can offer significant potential when supported by strong financials and solid fundamentals.

Simply Wall St. 3 months ago

FDMT
+3.59%

ANIX

HUIZ
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeksIn the recently diagnosed subgroup, which most resembles the Phase 3 4FRONT-1 and 4FRONT-2 patient populations, 87% required 0-1 supplemental injection and 80% were injection-free through 52 weeksDurable and stable aflibercept expression demonstrated across all 3E10 vg/eye PRISM cohorts, with up to two years of

GlobeNewswire 3 months ago

FDMT
+3.59%
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a Principal Investigator in PRISM, at Angiogenesis, Exudation, and Degeneration 2025 on Saturday, February 8, 2025 at 2:20 p.m. ETCompany to host webcast on Monday, February 10, 2025 at 8:00 a.m. ET to discuss the 4D-150 interim data including recently diagnosed subgroup, which most resembles the Phase 3 4FRONT-1 and -2 patient populations EMERYVILLE, Calif.

GlobeNewswire 4 months ago

FDMT
+3.59%
Top US Penny Stocks To Watch In January 2025

As the U.S. equities market takes a breather from its recent rally, major indices like the S&P 500 have reached new highs, reflecting investor optimism amid strong corporate earnings and pro-business policies. Despite their historical connotations, penny stocks remain an intriguing investment area due to their potential for growth when backed by robust financials. This article will explore three noteworthy penny stocks that demonstrate financial strength and offer potential opportunities for...

Simply Wall St. 4 months ago

CMCM

FDMT
+3.59%

HYLN
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosisAfter alignment with FDA and EMA on trial designs for the 4D-150 Phase 3 4FRONT program in wet AMD, 4FRONT-1 and 4FRONT-2 trials on track to initiate in Q1 2025 and Q3 2025 respectivelyPrimary endpoint 52-week topline data for both 4FRONT-1 and 4FRONT-2 expected in H2 2027Cash runway extended under updat

GlobeNewswire 4 months ago

FDMT
+3.59%
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level3E10 vg/eye demonstrated strong signals of clinical activity with sustained gain of BCVA of +8.4 letters and reduction of CST of -194 µm from baseline through Week 323E10 vg/eye achieved an 86% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W and dose response with 61% reduction vs. 1E10 vg/eye, with 0.6 mean supplemental inj

GlobeNewswire 4 months ago

FDMT
+3.59%
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent potentially best-in-class customized vectors and transformative genetic medicinesProprietary intravitreal vector R100 demonstrated superior transduction and transgene expression compared to AAV2, the standard AAV serotypes used in retinal gene therapies, in all three human retinal cell types evaluated in vitro (up to ~10-fold improvement), and in all pri

GlobeNewswire 5 months ago

FDMT
+3.59%

Performance Overview

Return	FDMT	S&P 500 (^GSPC)
YTD	-32.68%	+0.92%
1-Year	-84.36%	+12.48%
3-Year	-49.87%	+42.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

4D Molecular Therapeutics, Inc. (FDMT)

4DMT to Participate in Upcoming Investor Conferences

Spotlight On 3 Penny Stocks With Market Caps Under $500M

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

FDA awards RMAT status to 4DMT diabetic macular oedema therapy

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

Discover Fractyl Health And 2 More Promising Penny Stocks

Biotech stocks slide as Marks resignation seen being negative for sector

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

4D Molecular price target lowered to $35 from $39 at RBC Capital

4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Spotlight On February 2025's Promising Penny Stocks

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

Top US Penny Stocks To Watch In January 2025

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

Performance Overview